Spread the love
The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with COVID-19 along with plentiful neutrophils and macrophages will revivify growth prospects for the anti-inflammatory biologics market share during the forecast period. The ongoing trials for anti-tumor necrosis factor (TNF) antibodies in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis will aid the speedy expansion of the market during the forecast period, mentioned by Fortune Business Insights, in a report, titled “Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027” the market size stood at USD 64.84 billion in 2019. Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/anti-inflammatory-biologics-market-102733 Market Driver: Ongoing Trails for Anti-Tumour Necrosis Factor Therapy to Benefit COVID-19 Patients The increasing R&D investments by major players for the development of biologics will promote market growth in the forthcoming years. The rising number of deaths from coronavirus (COVID-19) has steered pharmaceutical companies to invest in potential drug candidates. The growing prominence of TNF in acute inflammatory reactions will have a positive impact on the market. Similarly, the ongoing research for anti-TNF therapy in patients with COVID-19 for counteraction and prevention will tremendously influence the market in the forthcoming years. Moreover, the advent of novel biological therapies and monoclonal antibodies by biopharma giants will facilitatethe healthy growth of the marketduring the forecast period. For instance, in December 2019, UCB S.A, a multinational biopharmaceutical company announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis.  Also, the escalation in applications of existing biologics for rare anti-inflammatory diseases such as lupus, diffuse systemic sclerosis, and others will enhance business scenarios of the market To get to know more about the short-term and long-term impact of COVID-19 on this market, Please Visit: https://www.fortunebusinessinsights.com/anti-inflammatory-biologics-market-102733 About Us: Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in. Contact Us: Fortune Business Insights™ Pvt. Ltd. US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245Email:sales@fortunebusinessinsights.com

Leave a Reply

Your email address will not be published. Required fields are marked *